US eClinical specialist Datatrak International has entered the Japanese market through a five-year Enterprise Agreement and Marketing Alliance with NTT Data Corporation, a Tokyo-based supplier of information system services.
Under the deal worth a minimum of around $2.4 million to Datatrak over the five-year term, NTT will become a value-added reseller of the Datatrak eClinical product suite to the Japanese clinical trials market.
It will also have the option to expand beyond the initially contracted volume of data items, subject to the demands of Japanese trial sponsors, and to sublicense the Datatrak eClinical Platform to trial sponsors and contract research organisations in Japan, as well as empowering those clients to become self-sufficient in their use of the information platform.
Through a five-year enterprise subscription licence agreement with Datatrak, NTT Data will standardise on the US company’s unified technology platform for clinical trial services delivered via a newly established Life Science Group. Until this group is fully conversant with the eClinical platform, Datatrak will provide these services for initial clinical trials.
$2.1 million upfront
NTT Data will pay Datatrak an upfront fee of $2.1 million and has committed to a five-year contract encompassing a fixed volume of data items. The total contract value of $2.4 million is a minimum amount as “any services provided by Datatrak or optional components of the Datatrak eClinical Platform outside of EDC (electronic data capture) or reporting (Data Genie) functionalities are contracted separately on an as needed basis”, the US company explained.
“The opportunity to have such a prominent alliance partner in Japan as a value-added reseller allows us to cost-effectively leverage the world’s second-largest pharmaceutical market with a high probability of rapid brand recognition and eventual business leverage,” commented Dr Jeffrey Green, president and chief executive officer of Datatrak International. “Intelligence reports from this market indicated that it is ripe for a new technology such as Datatrak eClinical that can offer a legitimate single-source Enterprise platform that is proven, reliable and scaleable.”
